LYTIX BIOPHARMA ASA: årsregnskap 2023 vs 2022
Shrank 77% on revenue, weaker earnings, cash halved-plus
approved 2024-05-14; registry 2024-07-15; journal 2024 619767
Summary
What changed
Comparing Årsregnskap 2023 with 2022 for LYTIX BIOPHARMA ASA. Revenue 17.27m NOK → 3.99m NOK (-76.9%). Net result -56.01m NOK → -87.90m NOK. Equity 135.13m NOK → 51.32m NOK.
Pressures included: revenue fell; operating result weakened; net result weakened.
Also worth watching: sharp cash drawdown; paid-in equity reduced; book investments changed. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.
At a glance
Scorecard
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 17.27m NOK to 3.99m NOK (-76.9% YoY). Calculated
-
↓
Operating result weakened
Operating result -65.70m NOK → -96.78m NOK (op. margin -380.3% → -2424.9%). Calculated
-
↓
Net result weakened
Net result -56.01m NOK → -87.90m NOK (net margin -324.2% → -2202.3%). Calculated
-
↓
Equity eroded
Book equity 135.13m NOK → 51.32m NOK (equity ratio 88898684.2% → 80.3%). Calculated
-
↓
Cash fell
Bank deposits 94.55m NOK → 27.37m NOK (-71.1% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (94.55m NOK → 27.37m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 135.13m NOK → 51.32m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Book investments changed
Investment / intangible book value 1.25m NOK → 438.2k NOK. Reported fact
-
·
Headcount (årsverk) changed
Reported FTEs 8.5 → 10. Reported fact